Goflikicept
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Goflikicept
- 1 338 interleukin 1 receptor accessory protein human fusion protein with peptide linker gsggg fusion protein with immunoglobulin fc fragment 134 cysteine 146 tryptophan 189 alanine de 227 lysine human 349 324 352 327 477 447 tris disulfide with 4 316 interleukin 1 receptor i human fusion protein with peptide linker gsggg fusion protein with immunoglobulin fc fragment 129 cysteine 146 serine 148 alanine 185 lysine 187 valine de 227 lysine human
- 1-338-INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN (HUMAN) FUSION PROTEIN WITH PEPTIDE LINKER (GSGGG) FUSION PROTEIN WITH IMMUNOGLOBULIN FC FRAGMENT (134-CYSTEINE,146-TRYPTOPHAN,189-ALANINE,DE-227-LYSINE) (HUMAN), (349->324'),(352->327'),(477->447')-(TRIS)DISULFIDE WITH 4-316-INTERLEUKIN 1 RECEPTOR I (HUMAN) FUSION PROTEIN WITH PEPTIDE LINKER (GSGGG) FUSION PROTEIN WITH IMMUNOGLOBULIN FC FRAGMENT (129-CYSTEINE,146-SERINE,148-ALANINE,185-LYSINE,187-VALINE,DE-227-LYSINE) (HUMAN)
- 80 mg rph 104
- 80 mg RPH-104
- goflikicept
- Goflikicept
- goflikicept [INN]
- Goflikicept [WHO-DD]
- goflikicept inn
- goflikicept who dd
- RPH - 104
- rph 104
- RPH 104
- rph 104 160 mg
- rph 104 320 mg
- rph 104 80 mg
- Rph-104
- RPH-104
- RPH-104 160 mg
- RPH-104 320 mg
- RPH-104 80 mg
- ATC classification codes
- L04AC26
Sources for recorded values
- CAS registry numbers
- 2416984-26-2
- ChEMBL ID
- CHEMBL4650513
- FDA ingredient codes (UNII)
- 11DRN01OK2
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -cept
- Condition
- Immune System Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Myocardial Infarction
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Still's Disease, Adult-Onset
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007135
- Subject identifier
- D016706
- Condition
- Pericarditis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007427
- Subject identifier
- D010493
- Condition
- Schnitzler Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001165
- Subject identifier
- D019873
- Condition
- Familial Mediterranean Fever
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018088
- Subject identifier
- D010505
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000540
- Condition identifier
- EFO_0000612
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007135
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007427
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001165
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005046
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005393
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005904
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018088
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018304
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019355
- Highest recorded phase
- 3
- NCT04213274
- NCT04380519
- NCT04463251
- NCT04692766
- NCT05107934
- NCT05673902
- NCT05092776
- NCT05190991
- NCT05432960
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (14)
- Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
- Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
- Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
- Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever
- Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
- Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers
- Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack
- Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
- Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
- Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
- Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
- Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
- Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis
In development for (8)
- Adult-onset Still disease Phase 3
- COVID-19 Phase 2
- Familial Mediterranean fever Phase 2
- Gout Phase 2
- Immune system disorder Phase 3
- Myocardial infarction Phase 2
- Pericarditis Phase 3
- Schnitzler syndrome Phase 2